S. Simón

发表

SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (HR+ with or without letrozole) in trastuzumab‐pretreated, postmenopausal patients with HER2‐positive metastatic breast cancer.

A. Prat, P. Villagrasa, J. Cortés, 2018 .

Critically short telomeres and toxicity of chemotherapy in early breast cancer

M. Blasco, A. Lluch, E. Zamora, 2017, Oncotarget.

Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications.

S. Simón, 2014 .

Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer

A. Lluch, P. Eroles, V. Constâncio, 2021, ESMO open.

Role of sentinel node biopsy in breast cancer: a review

J. Sebastià, A. Tejedor, S. Simón, 2021, European Journal of Gynaecological Oncology.

155PDTumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial

P. Nuciforo, A. Prat, M. Muñoz, 2017 .

Phase I study of the combination of balixafortide (CXCR4 inhibitor) and eribulin in HER2-negative metastatic breast cancer (MBC) patients (pts).

T. Pluard, F. Ademuyiwa, I. Mayer, 2017 .

130TiP SOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype

P. Villagrasa, X. Gonzalez-Farre, J. Cortés, 2021 .

124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trial

A. Prat, J. M. Ferrero-Cafiero, T. Pascual, 2023, ESMO Open.